Skip to main content
SpringerLink
Log in

Ovarian Cancer

  • Chapter
  • First Online:
Serous Effusions

  • 519 Accesses

Abstract

Both the peritoneal and pleural cavities may be the site of metastasis from ovarian tumors, though the former is more commonly involved. Dissemination to the pericardial cavity is uncommon. The differential diagnosis of ovarian metastases in serous effusions is critically dependent on the histology. While spreading from germ cell tumors and sex cord-stromal tumors may occasionally be seen, the vast majority of cases are metastases from ovarian carcinomas. Metastases from carcinosarcomas and involvement by borderline tumors, particularly serous, may be encountered as well. Carcinomas are predominantly of serous type, low-grade or high-grade, followed by clear cell carcinoma. Metastases from mucinous or endometrioid carcinoma are far less common. Serous carcinomas should be differentiated both from other carcinomas and from benign and malignant mesothelial cells, whereas in other histotypes the former differential diagnosis is usually more relevant. This chapter discusses the morphological and immunohistochemical characteristics of the different ovarian tumors that may be found in serous effusions and the differential diagnosis for each of these entities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed  Google Scholar 

  2. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Berek JS, Bast RC Jr. Ovarian cancer. In: Kufe DW, Bast Jr RC, Hait WM, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei III E, editors. Cancer medicine. 7th ed. Hamilton: BC Decker Inc.; 2006. p. 1543–68. Chapter 104.

    Google Scholar 

  4. Jacob IJ, Shepherd JH, Oran DH, Blackett AD, Luesley DM, Berchuck A, Hudson CN, editors. Ovarian cancer. Oxford: Oxford University Press; 2002.

    Google Scholar 

  5. Prat J. Ovarian, fallopian tube and peritoneal cancer staging: rationale and explanation of new FIGO staging 2013. Best Pract Res Clin Obstet Gynaecol. 2015;29:858–69.

    Article  PubMed  Google Scholar 

  6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.

    Article  PubMed  Google Scholar 

  7. Yang WL, Lu Z, Bast RC Jr. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017;17:577–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, Katsumata N, Burger RA, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers RLM, Casado Herráez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K. Participants of the 5th ovarian cancer consensus conference fifth ovarian cancer consensus conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol. 2017;28:711–7.

    Article  PubMed  CAS  Google Scholar 

  9. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IM. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2008;198:351–6.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237–49.

    Article  PubMed  Google Scholar 

  11. Singh N, McCluggage WG, Gilks CB. High-grade serous carcinoma of tubo-ovarian origin: recent developments. Histopathology. 2017;71:339–56.

    Article  PubMed  Google Scholar 

  12. Hirabayashi K, Graham J. The genesis of ascites in ovarian cancer. Am J Obstet Gynecol. 1970;106:492–7.

    Article  PubMed  CAS  Google Scholar 

  13. Feldman GB, Knapp RC, Order SE, Hellman S. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res. 1972;32:1663–6.

    PubMed  CAS  Google Scholar 

  14. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, Sioussat TM, Dvorak HF. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites tumor accumulation. Cancer Res. 1995;55:360–8.

    PubMed  CAS  Google Scholar 

  15. Nagy JA, Meyers MS, Masse EM, Herzberg KT, Dvorak HF. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res. 1995;55:369–75.

    PubMed  CAS  Google Scholar 

  16. Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak HF. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res. 1995;55:376–85.

    PubMed  CAS  Google Scholar 

  17. Sorbe B, Frankendal B. Prognostic importance of ascites in ovarian carcinoma. Acta Obstet Gynecol Scand. 1983;62:415–8.

    Article  PubMed  CAS  Google Scholar 

  18. Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol. 2002;87:77–83.

    Article  PubMed  Google Scholar 

  19. Rice LW, Mark SD, Berkowitz RS, Goff BA, Lage JM. Clinicopathologic variables, operative characteristics, and DNA ploidy in predicting outcome in ovarian epithelial carcinoma. Obstet Gynecol. 1995;86:379–85.

    Article  PubMed  CAS  Google Scholar 

  20. Ayhan A, Gultekin M, Taskiran C, Dursun P, Firat P, Bozdag G, Celik NY, Yuce K. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer. 2007;17:68–75.

    Article  PubMed  CAS  Google Scholar 

  21. Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol. 2001;82:532–7.

    Article  PubMed  CAS  Google Scholar 

  22. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer. 2001;85:944–52.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Puls LE, Duniho T, Hunter JE, Kryscio R, Blackhurst D, Gallion H. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol. 1996;61:109–12.

    Article  PubMed  CAS  Google Scholar 

  24. Makar AP, Baekelandt M, Tropé CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995;56:175–80.

    Article  PubMed  CAS  Google Scholar 

  25. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the gynecologic oncology group experience. J Clin Oncol. 1991;9:1138–50.

    Article  PubMed  CAS  Google Scholar 

  26. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ, Stage IV. Ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997;64:9–12.

    Article  PubMed  CAS  Google Scholar 

  27. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278–87.

    Article  PubMed  CAS  Google Scholar 

  28. Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, Shiromizu K, Kuzuya K, Kamura T, Kikuchi Y, Kodama S, Yamamoto K, Sato S. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001;81:398–403.

    Article  PubMed  CAS  Google Scholar 

  29. Bonnefoi H, A'Hern RP, Fisher C, Macfarlane V, Barton D, Blake P, Shepherd JH, Gore ME. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol. 1999;17:767–75.

    Article  PubMed  CAS  Google Scholar 

  30. Dauplat J, Hacker NF, Nieberg RK, Berek JS, Rose TP, Sagae S. Distant metastases in epithelial ovarian carcinoma. Cancer. 1987;60:1561–6.

    Article  PubMed  CAS  Google Scholar 

  31. Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol. 1997;64:4–8.

    Article  PubMed  CAS  Google Scholar 

  32. Jamieson A, Sykes P, Eva L, Bergzoll C, Simcock B. Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence. Gynecol Oncol. 2017;146:273–8.

    Article  PubMed  Google Scholar 

  33. Escayola C, Ferron G, Romeo M, Torrent JJ, Querleu D. The impact of pleural disease on the management of advanced ovarian cancer. Gynecol Oncol. 2015;138:216–20.

    Article  PubMed  Google Scholar 

  34. Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB, Cheryl Brown ovarian cancer outcomes unit of the British Columbia Cancer Agency, Vancouver BC. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29:203–11.

    Article  PubMed  Google Scholar 

  35. Pereira TC, Saad RS, Liu Y, Silverman JF. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol. 2006;13:174–84.

    Article  PubMed  Google Scholar 

  36. Yu GH, Sack MJ, Baloch ZW, DeFrias DV, Gupta PK. Occurrence of intercellular spaces (windows) in metastatic adenocarcinoma in serous fluids: a cytomorphologic, histochemical, and ultrastructural study. Diagn Cytopathol. 1999;20:115–9.

    Article  PubMed  CAS  Google Scholar 

  37. Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO classification of tumours of female reproductive organs. Lyon: IARC; 2014.

    Google Scholar 

  38. Ito H, Hirasawa T, Yasuda M, Osamura RY, Tsutsumi Y. Excessive formation of basement membrane substance in clear-cell carcinoma of the ovary: diagnostic value of the “raspberry body” in ascites cytology. Diagn Cytopathol. 1997;16:500–4.

    Article  PubMed  CAS  Google Scholar 

  39. Damiani D, Suciu V, Genestie C, Vielh P. Cytomorphology of ovarian clear cell carcinomas in peritoneal effusions. Cytopathology. 2016;27:427–32.

    Article  PubMed  CAS  Google Scholar 

  40. Ahr A, Arnold G, Göhring UJ, Costa S, Scharl A, Gauwerky JF. Cytology of ascitic fluid in a patient with metastasizing malignant Brenner tumor of the ovary: a case report. Acta Cytol. 1997;41(4 Suppl):1299–304.

    Article  PubMed  CAS  Google Scholar 

  41. Driss M, Mrad K, Dhouib R, Doghri R, Abbes I, Ben Romdhane K. Ascitic fluid cytology in malignant Brenner tumor: a case report. Acta Cytol. 2010;54:598–600.

    Article  PubMed  Google Scholar 

  42. Motoyama T, Watanabe H. Ascitic fluid cytologic features of a malignant mixed mesodermal tumor of the ovary. Acta Cytol. 1987;31:63–7.

    PubMed  CAS  Google Scholar 

  43. Ehya H, Lang WR. Cytology of granulosa cell tumor of the ovary. Am J Clin Pathol. 1986;85:402–5.

    Article  PubMed  CAS  Google Scholar 

  44. Lal A, Bourtsos EP, Nayar R, DeFrias DV. Cytologic features of granulosa cell tumors in fluids and fine needle aspiration specimens. Acta Cytol. 2004;48:315–20.

    Article  PubMed  Google Scholar 

  45. Kavuri S, Kulkarni R, Reid-Nicholson M. Granulosa cell tumor of the ovary: cytologic findings. Acta Cytol. 2010;54:551–9.

    Article  PubMed  Google Scholar 

  46. Gupta N, Rajwanshi A, Dey P, Suri V. Adult granulosa cell tumor presenting as metastases to the pleural and peritoneal cavity. Diagn Cytopathol. 2012;40:912–5.

    Article  PubMed  Google Scholar 

  47. Atilgan AO, Tepeoglu M, Ozen O, Bilezikçi B. Peritoneal washing cytology in an adult granulosa cell tumor: a case report and review of literature. J Cytol. 2013;30:74–7.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Omori M, Kondo T, Yuminamochi T, Nakazawa K, Ishii Y, Fukasawa H, Hashi A, Hirata S. Cytologic features of ovarian granulosa cell tumors in pleural and ascitic fluids. Diagn Cytopathol. 2015;43:581–4.

    Article  PubMed  Google Scholar 

  49. Murugan P, Siddaraju N, Sridhar E, Soundararaghavan J, Habeebullah S. Unusual ovarian malignancies in ascitic fluid: a report of 2 cases. Acta Cytol. 2010;54:611–7.

    Article  PubMed  Google Scholar 

  50. Valente PT, Schantz HD, Edmonds PR, Hanjani P. Peritoneal cytology of uncommon ovarian tumors. Diagn Cytopathol. 1992;8:98–106.

    Article  PubMed  CAS  Google Scholar 

  51. Ikeda K, Tate G, Suzuki T, Mitsuya T. Cytomorphologic features of immature ovarian teratoma in peritoneal effusion: a case report. Diagn Cytopathol. 2005;33:39–42.

    Article  PubMed  Google Scholar 

  52. Geisinger KR, Hajdu SI, Helson L. Exfoliative cytology of nonlymphoreticular neoplasms in children. Acta Cytol. 1984;28:16–28.

    PubMed  CAS  Google Scholar 

  53. Selvaggi SM, Guidos BJ. Immature teratoma of the ovary on fluid cytology. Diagn Cytopathol. 2001;25:411–4.

    Article  PubMed  CAS  Google Scholar 

  54. Selvaggi SM. Cytologic features of malignant ovarian monodermal teratoma with an ependymal component in peritoneal washings. Int J Gynecol Pathol. 1992;11:299–303.

    Article  PubMed  CAS  Google Scholar 

  55. Kashimura M, Tsukamoto N, Matsuyama T, Kashimura Y, Sugimori H, Taki I. Cytologic findings of ascites from patients with ovarian dysgerminoma. Acta Cytol. 1983;27:59–62.

    PubMed  CAS  Google Scholar 

  56. Hajdu SI, Nolan MA. Exfoliative cytology of malignant germ cell tumors. Acta Cytol. 1975;19:255–60.

    PubMed  CAS  Google Scholar 

  57. Roncalli M, Gribaudi G, Simoncelli D, Servida E. Cytology of yolk-sac tumor of the ovary in ascitic fluid. Report of a case. Acta Cytol. 1988;32:113–6.

    PubMed  CAS  Google Scholar 

  58. Davidson B, Abeler VM. Primary ovarian angiosarcoma presenting as malignant cells in ascites: case report and review of the literature. Diagn Cytopathol. 2005;32:307–9.

    Article  PubMed  Google Scholar 

  59. Hirakawa E, Kobayashi S, Miki H, Haba R, Saoo K, Yamakawa K, Ohkura I, Kira Y. Ascitic fluid cytology of adenosarcoma of the ovary: a case report. Diagn Cytopathol. 2001;24:343–6.

    Article  PubMed  CAS  Google Scholar 

  60. Delahaye M, van der Ham F, van der Kwast TH. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol. 1997;17:115–20.

    Article  PubMed  CAS  Google Scholar 

  61. Motherby H, Kube M, Friedrichs N Nadjari B, Knops K, Donner A, Baschiera B, Dalquen P, Böcking A. Immunocytochemistry and DNA-image cytometry in diagnostic effusion cytology I. Prevalence of markers in tumour cell positive and negative smears. Anal Cell Pathol. 1999;19:7–20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Maguire B, Whitaker D, Carrello S, Spagnolo D. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Diagn Cytopathol. 1994;10:130–4.

    Article  PubMed  CAS  Google Scholar 

  63. Davidson B, Risberg B, Kristensen G, Kvalheim G, Emilsen E, Bjåmer A, Berner A. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virchows Arch. 1999;435:43–9.

    Article  PubMed  CAS  Google Scholar 

  64. McKnight R, Cohen C, Siddiqui MT. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma. Cancer Cytopathol. 2010;118:298–302.

    Article  PubMed  Google Scholar 

  65. Tong GX, Devaraj K, Hamele-Bena D, Yu WM, Turk A, Chen X, Wright JD, Greenebaum E. Pax8: a marker for carcinoma of Müllerian origin in serous effusions. Diagn Cytopathol. 2011;39:567–74.

    Article  PubMed  Google Scholar 

  66. Zhao L, Guo M, Sneige N, Gong Y. Value of PAX8 and WT1 immunostaining in confirming the ovarian origin of metastatic carcinoma in serous effusion specimens. Am J Clin Pathol. 2012;137:304–9.

    Article  PubMed  Google Scholar 

  67. Wiseman W, Michael CW, Roh MH. Diagnostic utility of PAX8 and PAX2. immunohistochemistry in the identification of metastatic Mullerian carcinoma in effusions. Diagn Cytopathol. 2011;39:651–6.

    Article  PubMed  Google Scholar 

  68. Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer. 1998;84:101–8.

    Article  PubMed  CAS  Google Scholar 

  69. Davidson B, Baekelandt M, Shih IM. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol. 2007;35:756–60.

    Article  PubMed  Google Scholar 

  70. Kleinberg L, Holth A, Fridman E, Schwartz I, Shih IM, Davidson B. The diagnostic role of claudins in serous effusions. Am J Clin Pathol. 2007;127:928–37.

    Article  PubMed  CAS  Google Scholar 

  71. Lonardi S, Manera C, Marucci R, Santoro A, Lorenzi L, Facchetti F. Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions. Diagn Cytopathol. 2011;39:313–7.

    Article  PubMed  Google Scholar 

  72. Jo VY, Cibas ES, Pinkus GS. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Cancer Cytopathol. 2014;122:299–306.

    Article  PubMed  Google Scholar 

  73. Davidson B, Skrede M, Silins I, Shih IM, Trope’ CG, Flørenes VA. Low molecular weight cyclin E forms differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer. 2007;110:1264–71.

    Article  PubMed  CAS  Google Scholar 

  74. Reich R, Vintman L, Nielsen S, Kærn J, Bedrossian C, Berner A, Davidson B. Differential expression of the 67 kilodalton laminin receptor in malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol. 2005;33:332–7.

    Article  PubMed  Google Scholar 

  75. Davidson B, Stavnes HT, Hellesylt E, et al. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions. Hum Pathol. 2016;47:104–8.

    Article  PubMed  CAS  Google Scholar 

  76. Davidson B. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells. Hum Pathol. 2016;58:123–7.

    Article  PubMed  CAS  Google Scholar 

  77. Davidson B, Nielsen S, Christensen J, Asschenfeldt P, Berner A, Risberg B, Johansen P. The role of Desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol. 2001;25:1405–12.

    Article  PubMed  CAS  Google Scholar 

  78. Yuan Y, Nymoen DA, Tuft Stavnes H, Rossnes AK, Bjørang O, Wu C, Nesland JM, Davidson B. Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol. 2009;33:1673–82.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Wieczorek TJ, Krane JF. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations. Cancer. 2000;90:312–9.

    Article  PubMed  CAS  Google Scholar 

  80. Afify AM, Stern R, Michael CW. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol. 2005;32:145–50.

    Article  PubMed  Google Scholar 

  81. Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, Churg A. Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of. malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol. 2016;40:120–6.

    Article  PubMed  Google Scholar 

  82. Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, Bercich L, Bugatti M, Rossi G, Murer B, Barbareschi M, Giuliani S, Cavazza A, Marchetti G, Vermi W, Facchetti F. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28:1043–57.

    Article  PubMed  CAS  Google Scholar 

  83. Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, Ahadi MS, Farzin M, Toon CW, Gill AJ. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol. 2015;28:1360–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. Zhu W, Michael CW. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol. 2007;35:370–5.

    Article  PubMed  Google Scholar 

  85. Hecht JL, Lee BH, Pinkus JL, Pinkus GS. The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma. Cancer. 2002;96:105–9.

    Article  PubMed  Google Scholar 

  86. Ascoli V, Carnovale-Scalzo C, Taccogna S, Nardi F. Utility of HBME-1 immunostaining in serous effusions. Cytopathology. 1997;8:328–35.

    Article  PubMed  CAS  Google Scholar 

  87. Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol. 2006;30:878–82.

    Article  PubMed  Google Scholar 

  88. Hanna A, Pang Y, Bedrossian CW, Dejmek A, Michael CW. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol. 2010;38:264–9.

    PubMed  Google Scholar 

  89. Ordóñez NG. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol. 2006;13:16–25.

    Article  PubMed  Google Scholar 

  90. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109–15.

    Article  PubMed  CAS  Google Scholar 

  91. Hashi A, Yuminamochi T, Murata S, Iwamoto H, Honda T, Hoshi K. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol. 2003;22:374–7.

    Article  PubMed  Google Scholar 

  92. Han L, Pansare V, Al-Abbadi M, Husain M, Feng J. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. Diagn Cytopathol. 2010;38:333–6.

    PubMed  Google Scholar 

  93. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 2008;27:161–74.

    PubMed  Google Scholar 

  94. Kato N, Toukairin M, Asanuma I, Motoyama T. Immunocytochemistry for hepatocyte nuclear factor-1beta (HNF-1beta): a marker for ovarian clear cell carcinoma. Diagn Cytopathol. 2007;35:193–7.

    Article  PubMed  Google Scholar 

  95. Davidson B. Hepatocyte nuclear factor-1β is not a specific marker of clear cell carcinoma in serous effusions. Cancer Cytopathol. 2014;122:153–8.

    Article  PubMed  CAS  Google Scholar 

  96. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology. 2005;47:231–47.

    Article  PubMed  CAS  Google Scholar 

  97. Leroy X, Farine MO, Buob D, Wacrenier A, Copin MC. Diagnostic value of cytokeratin 7, CD10 and mesothelin in distinguishing ovarian clear cell carcinoma from metastasis of renal clear cell carcinoma. Histopathology. 2007;51:874–6.

    Article  PubMed  CAS  Google Scholar 

  98. Gokden N, Gokden M, Phan DC, McKenney JK. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol. 2008;32:1462–7.

    Article  PubMed  Google Scholar 

  99. Al-Ahmadie HA, Alden D, Qin LX, Olgac S, Fine SW, Gopalan A, Russo P, Motzer RJ, Reuter VE, Tickoo SK. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol. 2008;32:377–82.

    Article  PubMed  Google Scholar 

  100. Hynninen P, Vaskivuo L, Saarnio J, Haapasalo H, Kivelä J, Pastoreková S, Pastorek J, Waheed A, Sly WS, Puistola U, Parkkila S. Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology. 2006;49:594–602.

    Article  PubMed  CAS  Google Scholar 

  101. Sugai M, Umezu H, Yamamoto T, Jiang S, Iwanari H, Tanaka T, Hamakubo T, Kodama T, Naito M. Expression of hepatocyte nuclear factor 4 alpha in primary ovarian mucinous tumors. Pathol Int. 2008;58:681–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

    Ben Davidson M.D., Ph.D.

  2. Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

    Ben Davidson M.D., Ph.D.

Authors
  1. Ben Davidson M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ben Davidson M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Pathology, The Norwegian Radium Hospital Oslo University Hospital , Oslo, Norway

    Ben Davidson

  2. Department of Pathology, School of Medicine, Koç University, Istanbul, Turkey

    Pinar Firat

  3. UH Cleveland Medical Center, Case Western Reserve University, UH Clevel and Medical Center, Cleveland, Ohio, USA

    Claire W. Michael

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Davidson, B. (2018). Ovarian Cancer. In: Davidson, B., Firat, P., Michael, C. (eds) Serous Effusions. Springer, Cham. https://doi.org/10.1007/978-3-319-76478-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-76478-8_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-76477-1

  • Online ISBN: 978-3-319-76478-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation